Market:

Forcyte Biotechnologies, Inc. provides predictive disease models and screening technology for disease of cellular mechanobiology and mechanical force generation, which collectively represent hundreds of millions of dollars in annual preclinical R&D expenditures, and billions more in economic burden.

Technology:

Forcyte combines advances in microtechnology and automation to unlock access to cellular force generation as a quantitative metric in high-throughput screening and analysis. We build and deploy assays with direct links to functional pathophysiology that can be utilized by anyone with minimal training to obtain high-quality and functional data on cellular contraction, at the single-cell or multi- cellular levels.

Advantages:

• Automation-friendly (25/96/384-wellplate formats)
• Highly-parallelized (evaluates 100,000s of cells)
• Quantitative readout for cellular force generation
• Single-cell resolution
• No special expertise needed

Development Stage:

• Protoype

Patents Issued:

• "Device and method for force phenotyping of cells for high-throughput screening and analysis" (2018), PCT US20170176415A1

Select Publications:

• UCLA researchers develop method to accelerate cell force detection | The Daily Bruin
• Elastomeric sensor surfaces for high-throughput single-cell force cytometry | Nature

Contact:

Website: www.forcytebio.com
Email: Ivan Pushkarsky, ivan@forcytebio.com
Phone: 859-420-4398
LinkedIn

Back to Top